

ACHIEVEMENTS AND PERSPECTIVES OF MITOCHONDRIAL RESEARCH VOLUME II: BIOGENESIS

Proceedings of the International Symposium on Achievements and Perspectives in Mitochondrial Research held in Rosa Marina (Italy) on September 2-6, 1985.

Edited by

E. Quagliariello

E.C. Slater

F. Palmieri

C. Saccone

A.M. Kroon



1985

ELSEVIER SCIENCE PUBLISHERS
AMSTERDAM · NEW YORK · OXFORD

© 1985 Elsevier Science Publishers B.V. (Biomedical Division)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher, Elsevier Science Publishers B.V., Biomedical Division, P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

Special regulations for readers in the USA – This publication has been registered with the Copyright Clearance Center Inc. (CCC), 27 Congress Street, Salem, MA 01970, USA. Information can be obtained from the CCC about conditions under which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside the USA, should be referred to the copyright owner, Elsevier Science Publishers B.V., unless otherwise specified.

ISBN Volume II: 0-444-80746-2

ISBN Set of Volumes I and II: 0-444-80747-0

Published by:

Elsevier Science Publishers B.V. (Biomedical Division)

P.O. Box 211

1000 AE Amsterdam

The Netherlands

Sole distributors for the USA and Canada:

Elsevier Science Publishing Company Inc.

52 Vanderbilt Avenue

New York, NY 10017

USA

Library of Congress Cataloging in Publication Data

International Symposium on Achievements and Perspectives in Mitochondrial Research (1985: Rosa Marina, Italy) Achievements and perspectives of mitochondrial research.

Bibliography: p.

Includes index.

Contents: v. 1. Bioenergetics – v. 2. Biogenesis.


1. Mitochondria – Congresses. 2. Bioenergetics – Congresses. I. Quagliariello, Ernesto. II. Title.

QH603.M5156 1985 574.87'342 85-27596

ISBN 0-444-80747-0 (set)

ISBN 0-444-80745-4 (v. 1)

ISBN 0-444-80746-2 (v. 2)



Printed in The Netherlands

CONTENTS

Preface	V
---------	---

PLENARY LECTURES

Intron encoded proteins of mitochondria: Key elements of gene expression and genomic evolution Z. Kotylak, J. Lazowska and P.P. Slonimski	1
The mitochondrial genome as a target for chemotherapy of cancer A.M. Kroon and G. Van den Bogert	21

MITOCHONDRIAL GENE ORGANIZATION, GENE REARRANGEMENTS AND EVOLUTIONARY ASPECTS

Primary and higher order structural analysis of animal mitochondrial DNA C. Saccone, M. Attimonelli and E. Sbisà	37
Transmission genetics of mammalian mitochondria: A molecular model and experimental evidence W.W. Hauswirth and P.J. Laipis	49
Organization and evolution of invertebrate mitochondrial genomes D.R. Wolstenholme, D.O. Clary, J.L. MacFarlane, J.A. Wahleithner and L. Wilcox	61
The basis of diversity in yeast mitochondrial DNAs G.D. Clark-Walker, R.J. Evans, P. Hoeben and C.R. McArthur	71
Purification of yeast bI4 mRNA maturase from <i>E. coli</i> and from yeast. Nucleic acids binding properties A. Delahodde, J. Banroques, A.M. Becam, V. Goguel, J. Perea, R. Schroeder and C. Jacq	79
The organization and evolution of the mitochondrial genome of yeast: <i>ori</i> sequences, genes and intergenic sequences M. de Zamaroczy and G. Bernardi	89
Genomic organization and transcription of mitochondrial maxicircle DNA in trypanosomid protozoa L. Simpson, A.M. Simpson, V. de la Cruz, N. Neckelmann and M. Muhich	99

Recombination events associated with the cytochrome <i>c</i> oxidase subunit I gene in fertile and cytoplasmic male sterile maize and sorghum C.J. Leaver, P.G. Isaac, J. Bailey-Serres, I.D. Small, D.K. Hanson and T.D. Fox	111
Transfer RNAs of higher plant mitochondria: Gene localization and sequence determination L. Marechal, H. Wintz, J.M. Grienenberger, P. Guillemaut, G. Jeannin, J.H. Weil and D.M. Lonsdale	123
 RECOGNITION SIGNALS ON MITOCHONDRIAL NUCLEIC ACIDS	
Regulatory sequences for mammalian mitochondrial transcription and replication D.D. Chang, T.W. Wong, J.E. Hixson and D.A. Clayton	135
New insights into the mechanism of RNA synthesis and processing in human mitochondria G. Attardi, C. Doersen, G. Gaines, M. King, J. Montoya, C. Guerrier-Takada and S. Altman	145
Post-transcriptional modification of animal mitochondrial RNA: A methylation-dependent step in ribosomal RNA processing D.T. Dubin, D.L. Prince and R.M. Kotin	165
Nucleotide sequences involved in the control of transcription and displacement loop DNA synthesis for <i>Xenopus laevis</i> mtDNA D.F. Bogenhagen, S.S. Cairns and B.K. Yoza	175
The large ribosomal RNA gene of mitochondrial DNA of <i>Saccharomyces cerevisiae</i> : <i>In vitro</i> initiation of transcription and self-splicing of precursor RNA H.F. Tabak, A.H. Schinkel, M.J.A. Groot Koerkamp, G.T.J. Van der Horst, G. Van der Horst and A.C. Arnberg	183
Expression and function of the tRNA synthesis locus in <i>Saccharomyces cerevisiae</i> N.C. Martin, M.J. Hollingsworth, H.-H. Shu and D.R. Najarian	193
Transcription initiation and processing sites in the tRNA region of the yeast mitochondrial genome L. Frontali, S. Francisci, C. Palleschi, S. Stifani and E. Zennaro	203

Mechanism of integration of an intron within a mitochondrial gene: A double strand break and the transposase function of an intron encoded protein as revealed by <i>in vivo</i> and <i>in vitro</i> assays B. Dujon, G. Cottarel, L. Colleaux, M. Betermier, A. Jacquier, L. D'Auriol and F. Galibert	215
<i>cob</i> Intron 3 in yeast mtDNA: Nucleotide sequence and mutations in a novel RNA domain J. Holl, C. Schmidt and R.J. Schweyen	227
Mitochondrial introns and mitochondrial plasmids of <i>Neurospora</i> A.M. Lambowitz, R.A. Akins, G. Garriga, M. Henderson, A.R. Kubelik and K.A. Maloney	237
Molecular aspects of mitochondrial DNA and mitochondrial plasmids in <i>Claviceps purpurea</i> P. Tudzynski and A. Düvell	249
THE ASSIGNMENT OF THE MITOCHONDRIAL OPEN READING FRAMES	
Functional assignment of the products of the unidentified reading frames of human mitochondrial DNA A. Chomyn, P. Mariottini, M.W.J. Cleeter, C.I. Ragan, R.F. Doolittle, A. Matsuno-Yagi, Y. Hatefi and G. Attardi	259
The effect of long-term inhibition of mitochondrial protein synthesis on the oxidation capacity of mitochondria for NADH-linked substrates C. Van den Bogert, M. Holtrop, T. Melis, H. De Vries, S.P.J. Albracht and A.M. Kroon	277
The <i>Neurospora</i> mitochondrial stopper mutant, [E35], lacks two protein genes indispensable for the formation of complexes I, III and IV H. De Vries, J.C. De Jonge and C. Schrage	285
Gene organization and expression in <i>Neurospora crassa</i> mitochondria M.A. Nelson and G. Macino	293
Unassigned reading frames in the mitochondrial DNA of <i>Neurospora crassa</i> G. Burger	305
Mitochondrial translation of subunits of the rotenone-sensitive NADH: Ubiquinone reductase in <i>Neurospora crassa</i> W. Ise, H. Haiker and H. Weiss	317

Mitochondrial genes in trypanosomes: Abnormal initiator triplets, a conserved frameshift in the gene for cytochrome oxidase subunit II and evidence for a novel mechanism of gene expression R. Benne, J. Van den Burg, J. Brakenhoff, B. De Vries, P. Nederlof, P. Sloof and A. Voogd	325
Organization and expression of mitochondrial DNA in <i>Trypanosoma brucei</i> K. Stuart, D.P. Jasmer and J.E. Feagin	337
NUCLEOCYTOPLASMIC-MITOCHONDRIAL INTERRELATIONS; NUCLEAR GENES FOR MITOCHONDRIAL COMPONENTS	
The yeast mitochondrial <i>fit1</i> gene I.G. Macreadie, A.R. Zinn and R.A. Butow	349
Yeast nuclear gene products required for translation of specific mitochondrial messenger RNAs M.C. Costanzo, C.G. Poutre, C.A. Strick and T.D. Fox	355
Genetic approach to the nucleo-mitochondrial control of L- and D-lactate ferricytochrome c oxidoreductases expression in <i>Saccharomyces cerevisiae</i> I. Ferrero, T. Lodi, P. Goffrini and C. Donnini	361
Characterization of yeast nuclear genes coding for mitochondrial aminoacyl-tRNA synthetases A. Tzagoloff, M. Crivellone, A. Gampel, J. Hill, T.J. Koerner, A. Myers and L. Pape	371
Genes for mammalian mitoribosomal proteins T.W. O'Brien, S.F. Pietromonaco, M.A. Piatyszek and P.M. Gillevet	379
Transport of proteins into mitochondria: Receptors, recognition and transmembrane movement of precursors B. Schmidt, R. Pfaller, N. Pfanner, M. Schleyer and W. Neupert	389
The precursor of mitochondrial aspartate aminotransferase from chicken: Structures of protein, cDNA, and gene R. Jaussi, H. Gehring, R. Behra, J. Flueckiger, C.P. Sharma, D. Schuemperli, N. Juretić, B. Cotton and P. Christen	397
Strategies for manipulation of yeast mitochondrial genes and their products P. Nagley, T.A. Willson, M.J. Tymms, R.J. Devenish and D.P. Gearing	405

DEVELOPMENTAL ASPECTS AND MITOCHONDRIAL PATHOLOGY

Mitochondrial transcription in rat liver under different physiological conditions M.N. Gadaleta, P.L. Polosa, A. Lezza, F. Fracasso and P. Cantatore	417
Maternally inherited diseases of man D.C. Wallace, G. Singh, L.C. Hopkins and E.J. Novotny	427
Mitochondria and cancer D. Wilkie and K. Fearon	437
Mouse mitochondria and the cell surface M. Hirama and K.F. Lindahl	445
Reye's syndrome and abnormalities in mitochondrial structure and function: A biochemical study C.P. Lee, M.E. Martens, T.Y. Segalman and C.H. Chang	455
Tissue specific cytochrome deficiencies in human infants J.R. Aprille	465
Author index	477
Subject index	479

TRANSPORT OF PROTEINS INTO MITOCHONDRIA:
RECEPTORS, RECOGNITION AND TRANSMEMBRANE MOVEMENT OF PRECURSORS

B. SCHMIDT, R. PFALLER, N. PFANNER, M. SCHLEYER and W. NEUPERT, Institut für
Physiologische Chemie, University of Munich, Goethestr. 33, 8000 München 2, FRG

INTRODUCTION

Most of the mitochondrial proteins are coded for by nuclear genes, they are synthesized in the cytoplasm of the cell as precursor proteins and are then selectively imported by the mitochondria (1,2). The overall import appears to consist of a number of distinct sequential processes. The precursor proteins, most of which bear aminoterminal peptide extensions, bind to the mitochondrial surface and are then incorporated into the organelle. This transfer is irreversible and in most instances is dependent on an energized mitochondrial inner membrane. The next step in the assembly pathway is a processing reaction i.e. removal of the additional sequences and/or covalent modifications such as the attachment of heme in the case of cytochromes c and c_1 . Finally, the newly imported proteins reach their functional location and are assembled into active complexes.

Although we can distinguish individual steps of the import reaction, little is known about the components (apart from the precursor proteins) that participate in these reactions. In order to understand the molecular basis of import efforts are being made to define and characterize the components involved.

In this communication we describe experiments designed to elucidate the molecular mechanism of two aspects of protein transfer into mitochondria, viz. binding of the precursor proteins to the mitochondria, and their subsequent transmembrane movement or membrane insertion. The components responsible for binding, i.e. receptors, are proteins located on the surface of the mitochondria. Translocation directly from the binding sites is very rapid. On the other hand we demonstrate the existence of transmembrane intermediates, i.e. precursor proteins which are partly imported and span both inner and outer mitochondrial membranes. We propose an import pathway for inner membrane and matrix proteins via contact sites between inner and outer membrane.

MATERIALS AND METHODS

Established procedures were used to study import of proteins into mitochondria employing *in vitro* synthesized precursor proteins and isolated *Neurospora* mitochondria (3,4). The methods employed were as described elsewhere (4,5).

RESULTS

Binding of precursor proteins to mitochondria

The initial step in the import pathway subsequent to synthesis is the binding of the precursor to the mitochondria. Binding was usually observed in a reconstituted *in vitro* system when import was inhibited. This condition was achieved by destroying the membrane potential (e.g. for ADP/ATP carrier), by lowering the temperature (e.g. for porin) or by competitively inhibiting a processing step (e.g. for cytochrome c) (6-8). In the case of the above mentioned proteins, it was found that the binding sites (although probably distinct from each other) have common features: (i) they are saturable, (ii) they bind with high affinity, (iii) they appear to be proteins (Fig.1). The binding sites for porin (see Fig. 2) and ADP/ATP carrier appear to be located on the mitochondrial surface (6), whereas the apocytochrome c binding protein is located in the intermembrane space (9). The different location of these binding sites is also reflected by the differential sensitivity to




Fig. 1. High affinity binding of the precursor to the ADP/ATP carrier is mediated by proteinaceous receptors.

The precursor to ADP/ATP carrier was synthesized in a cell free system and partially purified by ammonium sulfate precipitation. Mitochondria were incubated with various concentrations of precursor under conditions where only binding takes place and subsequently reisolated. ADP/ATP carrier was immunoprecipitated from the supernatants and mitochondrial pellets. Quantification of the radioactivity associated with the carrier was carried out after excision of the carrier bands from an SDS gel. The amount of carrier bound to mitochondria is plotted versus the ratio bound/free (free = carrier recovered from the supernatants). Assuming a specific radioactivity of 3×10^4 cpm/pmol ADP/ATP carrier the number of binding sites was 1.7 pmol/mg mitochondrial protein and the K_d was $1.1 \times 10^{-6} M^{-1}$.
 + trypsin: mitochondria were treated with 5 μg of trypsin per/mg mitochondrial protein prior to the binding assay; - trypsin: untreated mitochondria.




Fig. 2. Binding of water-soluble porin to isolated mitochondria.

Binding of porin to its receptor was studied in a simplified assay system, in which isolated mitochondria and a water-soluble form of mitochondrial porin were incubated in buffer. The water-soluble porin was prepared from porin isolated from mitochondria with detergents, by removal of detergent and lipids and by controlled denaturation and renaturation (7). The water-soluble form acquired a number of properties of the membrane form after insertion into artificial lipid bilayers. After radioactive labelling by reductive methylation this water-soluble porin was employed to measure specific receptor sites on mitochondria.

A mitochondrial preparation (2 mg protein) in 1 ml 0.25 M sucrose, 10 mM Tris-HCl, 1 mM EDTA, pH 7.2 (SET) was divided into two halves. To one half 100 µg trypsin inhibitor was added together with 5 µg trypsin and incubation performed for 15 min at 25 °C. To the second half first 5 µg trypsin were added, the sample was incubated for 15 min at 25 °C and then 100 µg trypsin inhibitor were added. Both samples were incubated for 3 min at 25 °C and then for 10 min at 0 °C. Mitochondria were re-isolated, washed once in SET containing 100 µg/ml soybean trypsin inhibitor and resuspended in SET at a final concentration of 2 mg/ml. Binding of water-soluble porin to mitochondria was determined in samples which were prepared by mixing 125 µl reticulocyte lysate, 125 µl SET and 18 µl 0.1 M NaP_i, pH 6.8, containing 22 pmol water-soluble porin labelled with ¹⁴C by reductive methylation (specific radioactivity 82 µCi/µmol). Three different amounts of mitochondria were employed: 2,3 : 50 µg; 5,6 : 100 µg; 8,9 : 250 µg. Samples 1, 4 and 7 did not contain mitochondria and served to control binding to tube walls. Samples 2, 5 and 8 contained mitochondria pretreated with trypsin. Samples 3, 6 and 9 contained mitochondria pretreated with trypsin in the presence of trypsin inhibitor. After incubation for 20 min at 25 °C samples were centrifuged, the pellets resuspended, transferred to new tubes and centrifuged again. All were then dissolved in SDS containing buffer and subjected to gel electrophoresis. The dried gel was fluorographed.

proteases. It is reasonable to conclude that different types of interaction between precursor and receptor may exist depending on the structure and the location of the receptor.

That the receptor bound state is a true intermediate state in the assembly pathway has been shown by the fact that bound precursors can be directly

imported from the binding sites. This import is efficient and rapid. In the case of the ADP/ATP carrier the import is 20-30 times faster than the observed import of the free precursor (Fig.3) The receptors identified appear to be essential components of the import pathway and represent the initial mediators of the overall process.




Fig. 3. Kinetics of import of ADP/ATP carrier from receptor-bound state. Mitochondria were allowed to bind the precursor to the ADP/ATP carrier in the absence of a membrane potential (lanes 2-5, 7-10). As a control, import was allowed in lanes 1 and 6. After this first incubation mitochondria were reisolated and resuspended in fresh medium containing no precursors. The membrane potential was reestablished and import allowed for the indicated times. Then the samples were halved and either the ADP/ATP carrier directly immunoprecipitated (lanes 1-5) or assayed for assembled carrier as described in ref. 5 (lanes 6-10). The immunoprecipitates were resolved on SDS-PAGE and the gel was fluorographed.

Translocation of precursor proteins across mitochondrial membranes

We have also studied the translocation of precursors across the mitochondrial membranes, in particular the movement of proteins destined for the inner membrane and the matrix. This step requires an energized mitochondrial inner membrane. Recent studies have revealed that the import of ADP/ATP carrier into the inner membrane can be driven by a valinomycin mediated K^+ diffusion potential (Fig.4). This import cannot be abolished by addition of a protonophore. Furthermore, creation of a pH gradient does not stimulate import. These findings suggest that the membrane potential $\Delta\psi$ per se and not the total protonmotive force Δp (with the components $\Delta\psi$ and ΔpH) is the driving force for import (10). The molecular mechanism of the import, however, is still enigmatic and little is known at the moment about the putative constituents of a translocation machinery. Nevertheless, some details of the actual




Fig. 4. Import of ADP/ATP carrier driven by a K^+ diffusion potential. The precursor to ADP/ATP carrier was bound to mitochondria in the absence of a membrane potential. Mitochondria were reisolated and resuspended in fresh medium containing valinomycin and the indicated concentrations of KCl. After incubation, samples were treated with Proteinase K to assay for imported carrier which was then immunoprecipitated. The immunoprecipitates were resolved on SDS-PAGE and the gel was fluorographed. Results were quantitatively evaluated by densitometry.

translocation process have been unravelled. First of all, the membrane traversing step does not depend on nor is it obligatorily coupled to proteolytic processing (11). Secondly, the translocation appears to occur at sites of contact between inner and outer membrane. Translocation intermediates of the β -subunit of F_0F_1 -ATPase and of cytochrome c_1 have been observed, which are accessible from both the cytoplasmic and the matrix side of the membranes (4). These intermediates were observed when transfer *in vitro* of precursor proteins into mitochondria was carried out at low temperature (7°C). They could also be observed by coupling the precursor to its antibody prior to import and allow the complex to react with mitochondria (Fig.5). The complex between antibody and precursor is only partially imported even at room temperature. The orientation of these intermediates is such that the amino terminus is located in the matrix and thus can be cleaved by processing peptidase. The major part of the polypeptide chain remains in the cytoplasm and therefore is accessible to externally added protease. Interestingly the requirement of a membrane potential extends only to the formation of such a

transmembrane orientated intermediate (4). The rest of the polypeptide chain is translocated even in the absence of a membrane potential. Thus the membrane potential may have a triggering role in transmembrane movement of precursors.




Fig. 5. Transport into mitochondria of F₁β precursor bound to its antibody.

Import of the precursor to F₁β into isolated mitochondria was carried out with free precursor (A) or with precursor bound to its antibody (B). After incubation of the precursors with mitochondria, mitochondria were reisolated. F₁β was immunoprecipitated from the various reactions under the usual conditions (antibody + protein A-Sepharose) (A) or by just adding protein A-Sepharose (B). The immunoprecipitates were resolved by SDS-PAGE and fluorographed.

Lane 1: supernatant of reaction 2; lane 2: import into mitochondria; lane 3: binding to mitochondria in the absence of a membrane potential; lane 4: import into mitochondria and subsequent treatment with Proteinase K; lane 5: import into mitochondria, immunoprecipitation in the presence of an excess of antigen. p, precursor; m, mature F₁β.

DISCUSSION

Two of the components involved in the assembly of mitochondrial proteins have been characterized in some detail. These are the processing peptidase (12,13) and the receptors for precursor proteins. The import receptors recognize the precursor proteins and channel them to the mitochondria. It has been shown that the aminoterminal part of the precursor is responsible for the interaction with the mitochondrial import machinery (14,15). The nature of the interaction between precursor and receptor remains ill-defined.

Another unresolved question is: how do the precursors move from the receptor to a contact site and which proteins are involved in forming these sites. Possibly only the precursor and the receptor are required to form a contact site thus enabling the precursor to reach the inner membrane or the matrix. Since at least one of the translocation intermediates appears to be stable during fractionation of mitochondria efforts are being made to enrich and isolate these contact sites (16). The isolation and characterisation of the proteins constituting the transport machinery, would allow the reconstitution of import from isolated components and could lead to an understanding of the molecular basis of protein sorting and import by mitochondria.

ACKNOWLEDGEMENTS

We thank G. Karl, S. Meier, and C. Wagenpfeil for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (Ne-101/19-1) and by the Fonds der Chemischen Industrie.

REFERENCES

1. Harmey, M.A. and Neupert, W. (1985) in: *The Enzymes of Biological Membranes*, A. Martonosi ed., Plenum Publ. Co. New York, 4, 431-464.
2. Hay, R., Böhni, P., and Gasser, S. (1984) *Biochim. Biophys. Acta*, **779**, 65-87
3. Zwizinski, C., Schleyer, M., and Neupert, W. (1984) *J. Biol. Chem.* **259**, 7850-7856
4. Schleyer, M., and Neupert, W. (1985) *Cell*, in press
5. Schleyer, M., and Neupert, W. (1984) *J. Biol. Chem.* **259**, 3487-3491
6. Zwizinski, C., Schleyer, M., and Neupert, W. (1983) *J. Biol. Chem.* **258**, 4071-4074
7. Pfaller, R., Freitag, H., Harmey, M.A., Benz, R., and Neupert, W. (1985) *J. Biol. Chem.* **260**, 8188-8193
8. Hennig, B., and Neupert, W. (1981) *Eur. J. Biochem* **121**, 203-212
9. Köhler, H., Stuart, R., and Neupert, W. (1985) manuscript in preparation
10. Pfanner, N., and Neupert, W., (1985), *EMBO J.*, in press
11. Zwizinski, C., and Neupert, W. (1983) *J. Biol. Chem* **258**, 13340-13346
12. Böhni, P., Gasser, S., Leaver, C., and Schatz, G. (1980) in: *The Organization and Expression of the Mitochondrial Genome* (Kroon, A.M., and Saccone, C., eds.), Elsevier/North-Holland, Amsterdam, pp. 432-433
13. Schmidt, B., Wachter, E., Sebald, W., and Neupert, W. (1984) *Eur. J. Biochem.* **144**, 581-588

14. Hurt, E.C., Pesold-Hurt, B., and Schatz, G. (1984) *EMBO J.* **3**, 3149-3156
15. Horwich, A.L., Kalousek, F., Mellman, I., and Rosenberg, L.E. (1985) *EMBO J.* **4**, 1129-1135.
16. Schwaiger, H., and Neupert, W. (1985) manuscript in preparation

AUTHOR INDEX

- Akins, R.A., 237
 Albracht, S.P.J., 277
 Altman, S., 145
 Aprille, J.R., 465
 Arnberg, A.C., 183
 Attardi, G., 145, 259
 Attimonelli, M., 37
- Bailey-Serres, J., 111
 Banroques, J., 79
 Becam, A.M., 79
 Behra, R., 397
 Benne, R., 325
 Bernardi, G., 89
 Betermier, M., 215
 Bogenhagen, D.F., 175
 Brakenhoff, J., 325
 Burger, G., 305
 Butow, R.A., 349
- Cairns, S.S., 175
 Cantatore, P., 417
 Chang, C.H., 455
 Chang, D.D., 135
 Chomyn, A., 259
 Christen, P., 397
 Clark-Walker, G.D., 71
 Clary, D.O., 61
 Clayton, D.A., 135
 Cleeter, M.W.J., 259
 Colleaux, L., 215
 Costanzo, M.C., 355
 Cottarel, G., 215
 Cotton, B., 397
 Crivellone, M., 371
- D'Auriol, L., 215
 De Jonge, J.C., 285
 de la Cruz, V., 99
 Delahodde, A., 79
 Devenish, R.J., 405
 De Vries, B., 325
 De Vries, H., 277, 285
 de Zamaroczy, M., 89
 Doersen, C., 145
 Donnini, C., 361
 Doolittle, R.F., 259
 Dubin, D.T., 165
 Dujon, B., 215
 Düvell, A., 249
- Evans, R.J., 71
- Feagin, J.E., 337
 Fearon, K., 437
 Ferrero, I., 361
 Flueckiger, J., 397
 Fox, T.D., 111, 355
 Fracasso, F., 417
 Francisci, S., 203
 Frontali, L., 203
- Gadaleta, M.N., 417
 Gaines, G., 145
 Galibert, F., 215
 Gampel, A., 371
 Garriga, G., 237
 Gearing, D.P., 405
 Gehring, H., 397
 Gillevet, P.M., 379
 Goffrini, P., 361
 Goguel, V., 79
 Grienemberger, J.M., 123
 Groot Koerkamp, M.J.A., 183
 Guerrier-Takada, C., 145
 Guillemaut, P., 123
- Haiker, H., 317
 Hanson, D.K., 111
 Hatefi, Y., 259
 Hauswirth, W.W., 49
 Hawthorne, D.C., 1
 Henderson, M., 237
 Hill, J., 371
 Hirana, M., 445
 Hixson, J.E., 135
 Hoeben, P., 71
 Holl, J., 227
 Hollingsworth, M.J., 193
 Holtrop, M., 277
 Hopkins, L.C., 427
- Isaac, P.G., 111
 Ise, W., 317
- Jacq, C., 79
 Jacquier, A., 215
 Jasmer, D.P., 337
 Jaussi, R., 397
 Jeannin, G., 123
 Juretic, N., 397

- King, M., 145
 Koerner, T.J., 371
 Kotin, R.M., 165
 Kotylak, Z., 1
 Kroon, A.M., 21, 277
 Kubelik, A.R., 237
- Laipis, P.J., 49
 Lambowitz, A.M., 237
 Lazowska, J., 1
 Leaver, C.J., 111
 Lee, C.P., 455
 Lezza, A., 417
 Lindahl, K.F., 445
 Lodi, T., 361
 Lonsdale, D.M., 123
- MacFarlane, J.L., 61
 Macino, G., 293
 Macreadie, I.G., 349
 Maloney, K.A., 237
 Marechal, L., 123
 Mariottini, P., 259
 Martens, M.E., 455
 Martin, N.C., 193
 Matsuno-Yagi, A., 259
 McArthur, C.R., 71
 Melis, T., 277
 Montoya, J., 145
 Muhich, M., 99
 Myers, A., 371
- Nagley, P., 405
 Najarian, D.R., 193
 Neckelmann, N., 99
 Nederlof, P., 325
 Nelson, M.A., 293
 Neupert, W., 389
 Novotny, E.J., 427
- O'Brien, T.W., 379
- Palleschi, C., 203
 Pape, L., 371
 Perea, J., 79
 Pfaller, R., 389
 Pfanner, N., 389
 Piatyszek, M.A., 379
 Pietromonaco, S.F., 379
 Polosa, P.L., 417
 Poutre, C.G., 355
 Prince, D.L., 165
- Ragan, C.I., 259
- Saccone, C., 37
 Sbisà, E., 37
 Schinkel, A.H., 183
 Schleyer, M., 389
 Schmidt, B., 389
 Schmidt, C., 227
 Schrage, C., 285
 Schroeder, R., 79
 Schuemperli, D., 397
 Schweyen, R.J., 227
 Segalman, T.Y., 455
 Sharma, C.P., 397
 Shu, H.-H., 193
 Simpson, A.M., 99
 Simpson, L., 99
 Singh, G., 427
 Slonimski, P.P., 1
 Sloof, P., 325
 Small, I.D., 111
 Stifani, S., 203
 Strick, C.A., 355
 Stuart, K., 337
- Tabak, H.F., 183
 Tudzynski, P., 249
 Tymms, M.J., 405
 Tzagaloff, A., 371
- Van den Bogert, C., 21, 277
 Van den Burg, J., 325
 Van der Horst, G., 183
 Van der Horst, G.T.J., 183
 Voogd, A., 325
- Wahleithner, J.A., 61
 Wallace, D.C., 427
 Weil, J.H., 123
 Weiss, H., 317
 Wilcox, L., 61
 Wilkie, D., 437
 Willson, T.A., 405
 Wintz, H., 123
 Wolstenholme, D.R., 61
 Wong, T.W., 135
- Yoza, B.K., 175
- Zennaro, E., 203
 Zinn, A.R., 349

SUBJECT INDEX

- Actinomycin D: 148–156
 ADP/ATP carrier: 390, 392
 Aflatoxin B₁: 441
 Alkylating agents: 441
 Allantoin: 458–462
 Alu-palindromes: 288
 Amino aciduria: 473
 Aminoacyl tRNA synthetases: 371–378
 Amplification: 52, 94
 Anaerobiosis: 359
 Anti-maturase: 81–84
 Antimitochondrial drugs: 32, 437–444
 Antimycin A: 361–370
 Antisense RNA: 45
 Antisense strand: 143
Ascaris suum: 61–69
 Aspartate aminotransferase: 397–404
Aspergillus: 2, 227, 229–232, 261, 271, 289, 293, 305, 307, 324
 Aspirin: 439
 ATP synthase: 280, 393, 409–414
 ATP synthase genes: 101, 260–263, 322

 BHK cells: 165
 Bovine mitochondrial ribosomes: 379–387
Brettanomyces custersii: 72

 Calcium-metabolism, mitochondrial: 280, 437, 442, 455–464
 Cancer: 21–33, 437–444
 CCCP: 400
 Chemotherapy: 21–33, 437–440
 Chimericism: 52, 57
 Chloramphenicol: 265, 270, 290, 317–324
 Chloroplast genome: 112
Chlamydomonas reinhardtii: 282
 Chloripramine: 440
Claviceps purpurea: 249–256
 Cleavage-polyadenylation mechanism: 66
 CO, see: cytochrome *c* oxidase
 Codon usage: 81, 103, 130, 298, 309, 313
 Combined modality treatment: 31, 32
 Complementation: 242, 373
 Complex I, see: NADH-dehydrogenase
 Complex III, see: cytochrome *bc*₁ complex
 Complex IV, see: cytochrome *c* oxidase
 Coördinate expression: 3
 Cosmids: 125

 COX, see: cytochrome *c* oxidase
Crithidia fasciculata: 99, 101, 109, 325–336, 339
 C-terminal processing: 289
 Cycloheximide: 317–324
 Cycloleucine: 165–169, 358
 Cy RNA: 167–173
 Cytochrome *b* gene: 3, 5, 16, 17, 86, 100, 227–236, 260
 Cytochrome *bc*₁ complex: 21, 260, 322
 Cytochrome *c* oxidase, activity of: 22–31, 107, 121, 322, 418, 465
 Cytochrome *c* oxidase genes: 3, 5, 9, 16, 17, 21, 100, 101, 111–122, 188, 260, 325–336
 Cytochrome deficiency: 465–476
 Cytochromes spectrum: 367, 465–476
 Cytoduction: 7
 Cytostatic agents: 28, 31, 32
 Cytotoxic T lymphocytes: 445

 Deletions: 40, 73–77, 90, 232, 286, 341, 356
 Diaminopurine: 439
 Differentiation: 417–425
 Difluoromethylornithine (DMFO): 337
 Diversity of mitochondrial DNA: 71–78
 D-loop: 40, 41, 42, 51, 135–141, 175–182
 DNA-DNA hybridization: 5
 DNA-recombinase: 13, 16, 17
 Doxycycline: 25, 29, 30, 31
Drosophila yakuba: 61–69, 367
 Dual promoters: 196–198
 Duplications: 73–79, 93, 94
 Dyskinetoplasmic strains: 332

 Electron paramagnetic resonance: 278, 282
 Elongation factor EFTu, mitochondrial: 373
 Embryogenesis: 52, 57
 Emetine: 428
 Endonuclease: 7, 216
 Endosymbiosis: 380
 Energy-generating capacity: 21, 22, 31
 EPR, see: electron paramagnetic resonance
Escherichia coli: 79–88, 106, 188, 196, 221–224, 372
 Ethidium bromide: 76, 148, 153, 441
 Evolution, genomic: 1–20, 37–47, 49, 61–69, 71–78, 89–97, 99
 Evolutionary relationships: 1, 71–78, 339, 353, 359, 371, 376, 379, 385, 398
 Expression vector, yeast: 413

- Fibroblasts, chicken embryo: 398
 Filter binding assay: 87
 Finger printing analysis: 146, 259, 260
 Fit 1 gene: 349–354
 Frame shifts: 103, 287, 325–336, 356
 Fused proteins: 82, 410–414
- Gametogenesis: 49
 GC clusters: 91–96, 285, 299
 Gene expression: 1–20, 43, 81–82, 151, 293–304, 325–336, 337–346, 355–360, 361–370
 Gene processing: 6
 Gene rearrangements: 63, 73–77, 90, 117
 Genetic code: 66, 79–81, 103, 123, 130, 221, 296
 Glucose repression: 359
 Glycolysis: 22, 337, 437
 Gossypol: 439
 Guanylyltransferase: 198, 238
- Hamster cells (see also BHK cells): 291
 Heavy strand promoter = HSP: 135, 177
 HeLa cells: 145–163, 169, 259–275, 307, 418–421
 Hepatectomy, partial: 23, 24
Herpetomonas samuelpessoai: 99
 Heteroduplex analysis: 113
 Heteroplasmy: 50–58, 358, 428
 Histocompatibility complex: 445–454
 HM protein: 85
 Human hepatoma: 383
 Hybridization experiments: 75, 126, 170, 178, 187, 207, 250, 335, 419, 433
 Hybridoma: 449
- Immunodetection: 83, 84, 239, 259–271, 381, 393, 428
 Immunosuppression: 32
 Induction: 361–370
 Initiation codon: 65, 66, 325–336
 Initiation of transcription: 136
 Insertion: 40, 90, 217, 232
 Intergenic sequences: 89–97, 135, 183, 203, 209, 213
 Intervening sequences: 1, 3
 Intron encoded proteins: 1–20, 79
 Introns, mitochondrial: 1–20, 79, 90, 183, 215–225, 227–236, 237–247, 295–298, 305, 313, 358
 Inversion: 63
 Inverted repeats: 339
 In vitro transcription system: 148, 152, 175, 183–191
 Isozymes, tissue-specific: 465–476
- Keratocytes: 438
 Killer cells: 445
 Kinetoplast DNA: 99–110, 325–366, 337–346
Kluyveromyces: 2, 252, 255
- D-lactate ferricytochrome *c* oxidoreductase: 361–370
 L-lactate ferricytochrome *c* oxidoreductase: 361–370
- Lariats: 188
 Leader sequence: 155, 355–360
Leishmania tarentolae: 99–110, 272, 325, 335, 339
Leptomonas: 99, 109
 Lewis lung carcinoma (L1210): 439
 Leydig cell tumor: 28, 278
 Light strand promoter = LSP: 135, 136, 176, 177, 180
 Liver regeneration: 23, 24
 Ludiomil: 439
- Maize: 111–122, 252, 255, 272
 Male sterility, cytoplasmic: 111–122, 123–132
 Manipulation of genes: 405–414
 Maternal inheritance: 49–59, 427–436, 445–454, 465–476
 Maturase: 3, 5, 9, 10, 11, 13, 79–88, 183, 188, 231, 287, 298, 306
 Mauriceville plasmid: 243–245
 Maxicircle DNA: 99–110, 325–336, 337–346
 Meiosis: 55–58
 Membrane potential: 392–394
 Methylation: 165–174
 Methyltransferases: 165
 Minicircle DNA: 99, 325, 332–336, 337–339, 345
 Mitochondrial DNA of animals: 37–47, 259–275, 427
 Mitochondrial DNA of invertebrates: 61–69, 79, 99–110, 249–256, 293–304, 325–336
 Mitochondrial DNA of plants: 111–122, 123–132
 Mitochondrial genes, primary structure: 37–40, 77, 89–97
 Mitochondrial meiosis, see: meiosis
 Mitochondrial plasmids: 243–247, 249–256
 Mitochondrial protein synthesis: 23–32, 221, 259, 277–283, 320
 mRNA genes: 38
 Mta = maternally transmitted antigen: 445–454
Mus castaneus: 447
Mus spretus: 447
 Mutagenesis: 79–81, 216, 372, 403, 409
 Mutations: 9, 16, 355
- Kalilo variants: 245

- Mutations, cis-dominant: 9, 16
 Mutations, trans-recessive: 9
 Myoclonic epilepsy: 429
 Myopathy: 429, 473

 NADH-dehydrogenase: 21, 61, 63, 156, 264–273, 277–283, 285, 306–309, 313, 317–324
 ND subunits, see: NADH-dehydrogenase
 Neurodegenerative disease: 427–432
Neurospora crassa: 2, 94, 188, 237–247, 254, 271, 277–283, 285–292, 293–304, 305–316, 317–324, 389–396
Neurospora intermedia: 243, 245
Neurospora tetrasperma: 243
 Nick-translation: 402
 Nonanucleotide box: 184, 186, 194, 207, 212
 Northern analysis: 12, 120, 188, 194, 196, 212, 241, 384, 422
 Nuclear genes: 355–360, 361–370, 371–378, 379–387
 Nucleic acids wielding proteins: 17, 18
 Nucleo-mitochondrial incompatibility: 7, 12, 13
 Nucleotidyltransferase: 145

 Oligo(dT)-cellulose: 156, 157
 Oligomycin resistance: 408
 Oligonucleotide directed mutagenesis, see: mutagenesis
 Oncogenes: 442
 Oögenesis: 53–57, 175
 Open reading frame: 2, 11, 91, 94, 100, 119, 215, 221, 229, 298, 306, 311, 312
 Origin of replication: 40, 62, 135–144, 176
Ori-sequences: 89–97, 408
 ORF, see: open reading frame
 Ornithine decarboxylase: 337
 Oxidative phosphorylation: 21, 271, 277–283, 285, 417–421, 465–476
 Oxytetracycline: 23, 24, 25, 277

 Phylogeny: 39
 Piercidin A: 280, 290
 Plasma membrane: 31, 441, 445–454
Podospora: 2, 254, 307
 Polyadenylation: 145, 151, 158, 168–172, 341
 Polycistronic RNA: 145, 148, 161, 203, 286
 Polynucleotide kinase: 176
 Porin: 390
 Posttranscriptional modification: 165–174, 341–345, 355
 Primer extension product: 197, 204–207
 Priming signals: 136, 140, 141, 176, 180, 327

 Proflavine: 153
 Proliferation arrest: 23–32, 440
 Promoter sites: 40, 82, 95, 105, 113, 135–144, 152, 159, 173, 177, 180, 183, 194–197, 301, 342
 Pronase: 147
 Protonmotive force: 392
 Pseudogenes: 103, 107, 331, 385
 PstI-palindrome: 238, 244, 286, 299, 301
 Pyridoxal-5'-phosphate: 401

 Rat liver: 277–283, 417–425
 Receptors; 389–396
 Recombinant plasmids: 87, 124, 148, 159, 175, 184, 221–224, 252, 371, 402, 406
 Recombination: 7, 13, 16, 17, 50, 77, 95, 111–122, 123, 301
 Renal carcinoma: 28
 Replication: 40, 42, 43, 56, 93, 94, 135–144
 Restriction mapping: 12, 17, 50, 111, 119, 176, 178, 245, 249, 334
 Restriction site polymorphism: 51, 428, 451
 Reverse transcription: 6, 159, 243, 327, 331
 Revertants: 117, 356
 Reye's syndrome; 455–464
 Rhodamine: 439
 Ribosome assembly: 240, 313, 379–387
 Ribosome binding site: 44
 Ribosomal proteins: 379–387
 RNA, ribosomal: 6, 106, 150
 RNA-editing: 332
 RNA-maturase, see: maturase
 RNA-polymerase: 150, 152, 159, 175, 178, 180, 183, 422
 RNA-processing: 95, 145–163, 165–174, 183–191, 193–202, 203–214, 237–247, 286, 301, 341, 342, 358, 381
 RNA-splicing, see: splicing
 RNase: 140, 146
 RNase H: 158, 161
 RNase P: 145–148, 161, 193, 198–201, 203
 RNase T1: 178, 184, 198
 Roser T-cell leukaemia: 28–31
 rRNA genes: 38, 44, 63, 65, 90, 100, 113, 150, 183–191, 312, 325, 340
 Run-off transcription: 139, 184, 188

 S 1 nuclease: 149, 170–171, 175, 178, 181, 204–207, 331, 422
 S-5, ribosomal protein: 239, 298
Saccharomyces carlsbergensis: 89
Saccharomyces cerevisiae: 2–17, 71–78, 79, 89–97,

- 183–191, 193–202, 203–214, 215–225, 227–236, 262, 271, 293, 309, 349–354, 355–360, 361–370, 371–378, 405–414
- Saccharomyces douglasii*; 7–17
- Saccharomyces exiguus*; 72
- Salicylate: 458–460
- Schizosaccharomyces*: 2, 72, 231, 262, 271, 309
- Secale cereale*: 256
- Segregation: 52, 428–434, 447
- Self-splicing: 3, 186–189, 215, 237, 241, 288
- Sequence variation of mtDNA: 49, 73–77, 90
- Signal peptide: 356, 369, 376, 389–396, 397–404, 410
- Sodium dodecyl sulphate = SDS: 266
- Sorghum: 111–122
- Southern analysis: 12, 17, 170, 250, 253, 334, 385, 433
- Splicing: 3, 9, 79–88, 104, 183–191, 234, 240, 288, 306, 331, 355
- Splicing deficient mutants: 5, 9, 11
- Stem cells; 28, 31
- Slopper mutants: 245, 285–292
- Substitutions of bases (silent/replacement): 38, 39, 67
- Succinate-ubiquinone oxidoreductase = succinate dehydrogenase: 265, 280
- Suppressors: 234, 356
- Symmetric transcription: 213
- Synchronization: 32
- Synthetic genes: 409–413
- Termination signals: 150, 152, 176
- Tetracyclines: 21–33
- Tetrad analysis: 363–366
- Tetrahymena*: 3, 105, 186, 227, 237, 240
- Thyroid hormone: 417–425
- Torulopsis glabrata*: 72
- Transcription: 105–107, 113, 135–144, 145–163, 175–182, 203–214, 301, 341–345, 417–425
- Transesterification: 5, 240
- Transformation: 405–414
- Translation: 355–360, 368
- Translation slippage: 287
- Translocation: 63, 94
- Transmembrane movement: 389–396
- Transmission of mitochondrial genes: 49–59
- Transport of proteins: 389–396
- Transposable elements; 18, 215, 237, 243, 442
- Transposase: 215–225
- Transposition, duplicative: 6, 215, 220, 237
- tRNA genes: 38, 40, 63, 65, 105, 123–132, 203–214
- tRNA synthesis locus: 193–202
- Trypanosoma brucei*: 99–108, 272, 307, 325–336, 337–346
- Trypanosoma cruzi*: 99, 339
- Trypanosoma equiperdum*: 339
- Trypanosoma evansi*: 332
- Trypanosoma lewisii*: 339
- Trypanosomes: 99–110, 325–336
- Tumors/tumor cells: 21–33
- Unidentified (unassigned) reading frame: 61, 259–275, 277, 285–292, 294, 296, 305–316, 327
- Universal mitochondrial genes: 273
- URF, see: unidentified reading frame
- Uric acid: 455–464
- Valinomycin: 392
- Var 1* gene: 90, 94, 371
- Variant surface glycoprotein (VSG): 332
- Varkud plasmid: 243–245
- Walker sarcoma: 28, 440
- Western analysis: 83, 84, 239, 382
- Xenopus*: 45, 175–182
- Zajdela hepatoma: 23, 25, 28